Skip to content

Usefulness of GI-GENIUS in FIT-based Colorectal Cancer Screening Program.

Usefulness of GI-GENIUS in FIT-based Colorectal Cancer Screening Program. Randomized Controlled Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04673136
Acronym
CADILLAC
Enrollment
3400
Registered
2020-12-17
Start date
2021-04-01
Completion date
2022-03-31
Last updated
2022-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma Colon, Colonic Polyp, Colorectal Cancer, Colorectal Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Serrated Adenoma, Serrated Polyp

Brief summary

Deep learning technology has an increasing role in medical image applications and, recently, an artificial intelligence device has been developed and commercialized by Medtronic for identification of polyps during colonoscopy (GI-GENIUS). This kind of computer-aided detection (CADe) devices have demonstrated its ability for improving polyp detection rate (PDR) and the adenoma detection rate (ADR). However, this increase in PDR and ADR is mainly made at the expense of small polyps and non advanced adenomas. Colonoscopies after a positive fecal immunochemical test (FIT) could be the scenario with a higher prevalence of advanced lesions which could be the ideal situation for demonstrating if these CADe systems are able also to increase the detection of advanced lesions and which kind of advanced lesions are these systems able to detect. The CADILLAC study will randomize individuals within the population-based Spanish colorectal cancer screening program to receive a colonoscopy where the endoscopist is assisted by the GI-GENIUS device or to receive a standard colonoscopy. If our results are positive, that could suppose a big step forward for CADe devices, in terms of definitive demonstration of being of help for efectively identify also advanced lesions.

Interventions

DEVICEGI-GENIUS Medtronic

Colonoscopy assisted by GI-GENIUS device

OTHERColonoscopy

Standard colonoscopy

Sponsors

Medtronic
CollaboratorINDUSTRY
Asociación Española de Gastroenterología
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals with a positive result in fecal immunochemical test within the population-based colorectal cancer screening program. * Complete colonoscopy with cecal intubation. * Inform consent signed.

Exclusion criteria

* Personal history of colorectal cancer. * Family history of colorectal cancer: ≥2 FDR or ≥1 FDR diagnosed before 50 years of age. * Family history of hereditary colorectal cancer syndromes: Lynch syndrome, FAP, etc. * Personal history of inflammatory bowel disease. * Terminal illness. * Personal history of total proctocolectomy.

Design outcomes

Primary

MeasureTime frameDescription
Detection of advanced lesions15 monthsTo determine the impact of the GI-GENIUS device as an assistant to the endoscopist to detect advanced lesions (advanced adenomas and advanced serrated polyps) in FIT-based screening colonoscopies.

Secondary

MeasureTime frameDescription
Detection of other type of lesions15 monthsTo determine the ability of the GI-GENIUS device to detect other lesions (colorectal cancer, adenomas, advanced adenomas, serrated polyps, advanced serrated polyps, non-polypoid lesions ≥10mm and right-sided advanced adenomas)
Characteristics of GI-GENIUS1 monthTo describe the characteristics of using the GI-GENIUS device during a colonoscopy: withdrawal time, false-positive and false-negative rate of advanced lesions using the device, etc.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026